In this work, we show that myeloid-specific deletion of METTL3, the catalytic subunit of the methyltransferase complex, enhances tumour growth and metastasis in mouse tumour models and attenuates PD-1 blockade therapy via influencing macrophage reprogramming. The gene discussed is METTL3; the disease is neoplasm.